Mechanism of ômega-3 fatty acids in the inflammatory process via GPR120 in blood cells of Overweight individuals with Non-Alcoholic Fatty Liver Disease - MOIGO: MECHANISM OF ÔMEGA-3 in inflammation via GPR12 in overweight individuals

FCA Unicamp0 个研究点开始时间: 2019年10月1日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients with excess body weight (body mass index (BMI) greater than or equal to 25.0 kg / m2) between the ages of 19 and 75, of both sexes, diagnosed by the physician of the Hospital Universitário, Universidade Federal de Sergipe, Hepatology Outpatient Clinic with fNon-alcoholic fatty liver disease (NAFLD), as a result of the presence of fat in the liver by ultrasonography, negative serological results for hepatitis B and C, absence of autoimmune diseases, absence of current or previous clinical history of alcohol abuse, absence of other liver diseases caused toxins or metabolites (eg corticosteroids, high doses of estrogen, methotrexate, tetracycline, calcium channel blockers, amiodarone or tamoxifen). The patients should be residents of the Aracaju Metropolitan Region, which is composed by the cities of Aracaju, Nossa Senhora do Socorro, Barra dos Coqueiros and São Cristovão.

•Patients pregnant, nursing, allergic to fish and crustaceans, smokers, carriers of diseases that can lead to change in body weight such as hypo or hyperthyroidism, hypogonadism, hyperandrongenism in women, Cushing's syndrome and other types of secondary obesity, as well chronic kidney disease, cancers and inflammatory bowel disease. Also excluded are individuals taking anti-inflammatory drugs and who in the last three months prior to the study made use of nutritional supplements such as vitamins, minerals, oils and fats or those who are doing some treatment for weight loss and those who have lost more than 10% body weight in the last month.

发起方

FCA Unicamp